


SOL Group

First Half 2026 Results



SOL GROUP | Revenues

Sales development (H1 2026)




June 2026 vs June 2025

- + 7,2 % organic growth
- + 1,6 % M&A
- 0,3 % FX effect


> 8.000 employees

+11,3%
vs previous year

+7,7%
vs previous year



+5,5%
vs previous year




+9,1%
vs previous year


SOL GROUP | Results

EBITDA and EBIT (H1 2026)

EBITDA [M€] & Margin [%]




EBIT [M€] & Margin [%]




SOL | Technical Gases

Sales & EBITDA (H1 2026)

Sales development [M€]



EBITDA [M€] & Margin [%]



SOL | Technical Gases

Industrial Production

eurostat 

Industrial production

% change compared with same month of the previous year*




	Jan-26	Feb-26	Mar-26	Apr-26	May-26	Jun-26
Euro area	-1.1	-1.0	-2.8	0.4	-0.1	0.1
EU	-0.4	-0.5	-1.6	0.9	0.6	0.6
Italy	-0.6	0.4	1.4	1.1	1.2	-0.6
Germany	-1.2	-0.1	-4.1	-1.1	-0.6	-0.5
France	1.8	-0.6	1.3	2.8	3.0	-0.5


VIVISOL | Home Care

Sales & EBITDA (H1 2026)

Sales development [M€]



EBITDA [M€] & Margin [%]




933.000 patients
+12,9%
vs previous year


SOL GROUP | Ratios

Investments and Net Profit (H1 2026)

Net Profit of the Year




CAPEX of the year (excl. M&A)



SOL GROUP | Ratios

Net Financial Position (2026)

Net Financial Position & Cash Flow Cover



SOL GROUP | Seizing opportunities despite difficult contexts

Mergers and acquisitions (2026)

UK – Home Care

DIVERSIFICATION through

REMEO Center of excellence for complex mechanical ventilation, following the renowned rehabilitation-focused "Lane Fox" clinical model to support long-term patients outside of intensive care.



SWITZERLAND – Home Care

REINFORCEMENT through

VITALAIRE Leader in home respiratory care provider serving over 6,000 patients with advanced services in sleep apnea, mechanical ventilation, and oxygen therapy.



ITALY – Home Care

DIVERSIFICATION through

HAEMOPHARM BIOFLUIDS Founded in 2002 and acquired by Medtronic/Mozarc Medical Group in 2016, Haemopharm Biofluids manufactures infusion drugs and dialysis solutions in Tovo di Sant'Agata (Sondrio).



BRAZIL – Home Care

REINFORCEMENT of presence through **OXYGENAR** Brazilian home care provider founded over 15 years ago by CEO Ivan Vitor Machado da Silva. Following its rapid growth across Rio de Janeiro, São Paulo, and the acquisition of **Pulmonair**, Oxygenar now operates a network of 24 sleep centers dedicated to personalized oxygen therapy, sleep apnea, and mechanical ventilation services.



SOL GROUP | Seizing opportunities despite difficult contexts

Mergers and acquisitions (2026) - IBG

**IBJV Participações Ltda
(SOL Group)**
51%

**Mr. Newton de
Oliveira**
49%

**Industria Brasileira de Gases S.A.
(IBG)**

- € 35 millions gross revenues
- 258 employees
- 4 Air Separation Units
+ 1 Under Construction
- 3 CO2 plants




SOL GROUP | Seizing opportunities despite difficult contexts

Mergers and acquisitions (2026) – Nowus Healthcare

**Nowus
Healthcare A/S
100%**

- € 6,9 million revenues

- 14 employees



SOLGROUP
a breath of life

solgroup.com